[1]
|
中华中医药学会风湿病分会. 痛风和高尿酸血症病证结合诊疗指南[J]. 中医杂志, 2021, 62(14): 1276-1288.
|
[2]
|
Li, Q., Li, X., Wang, J., et al. (2019) Diagnosis and Treatment for Hyperuricemia and Gout: A Systematic Review of Clinical Practice Guidelines and Consensus Statements. BMJ Open, 9, e26677.
https://doi.org/10.1136/bmjopen-2018-026677
|
[3]
|
Sapankaew, T., Thadanipon, K., Ruenroengbun, N., et al. (2022) Efficacy and Safety of Urate-Lowering Agents in Asymptomatic Hyperuricemia: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. BMC Nephrology, 23, Article No. 223. https://doi.org/10.1186/s12882-022-02850-3
|
[4]
|
Zhang, L., An, K., Mou, X., et al. (2022) Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 12, Article ID: 795082. https://doi.org/10.3389/fphar.2021.795082
|
[5]
|
Yang, L., Wang, B., Ma, L., et al. (2022) Traditional Chinese Herbs and Natural Products in Hyperuricemia-Induced Chronic Kidney Disease. Frontiers in Pharmacology, 13, Article ID: 971032.
https://doi.org/10.3389/fphar.2022.971032
|
[6]
|
Maiuolo, J., Oppedisano, F., Gratteri, S., et al. (2016) Regulation of Uric Acid Metabolism and Excretion. International Journal of Cardiology, 213, 8-14. https://doi.org/10.1016/j.ijcard.2015.08.109
|
[7]
|
Narang, R.K. and Dalbeth, N. (2020) Pathophysiology of Gout. Seminars in Nephrology, 40, 550-563.
https://doi.org/10.1016/j.semnephrol.2020.12.001
|
[8]
|
Xu, L., Shi, Y., Zhuang, S., et al. (2017) Recent Advances on Uric Acid Transporters. Oncotarget, 8, 100852-100862.
https://doi.org/10.18632/oncotarget.20135
|
[9]
|
Le, M.T., Shafiu, M., Mu, W., et al. (2008) SLC2A9—A Fructose Transporter Identified as a Novel Uric Acid Transporter. Nephrology Dialysis Transplantation, 23, 2746-2749. https://doi.org/10.1093/ndt/gfn349
|
[10]
|
Dehghan, A., Köttgen, A., Yang, Q., et al. (2008) Association of Three Genetic Loci with Uric Acid Concentration and Risk of Gout: A Genome-Wide Association Study. The Lancet, 372, 1953-1961.
https://doi.org/10.1016/S0140-6736(08)61343-4
|
[11]
|
Wang, H., Zhang, H., Sun, L., et al. (2018) Roles of Hyperuricemia in Metabolic Syndrome and Cardiac-Kidney-Vascular System Diseases. The American Journal of Translational Research, 10, 2749-2763.
|
[12]
|
Komori, H., Yamada, K. and Tamai, I. (2018) Hyperuricemia Enhances Intracellular Urate Accumulation via Down-Regulation of Cell-Surface BCRP/ABCG2 Expression in Vascular Endothelial Cells. Biochimica et Biophysica Acta—Biomembranes, 1860, 973-980. https://doi.org/10.1016/j.bbamem.2018.01.006
|
[13]
|
Mallat, S.G., Al, K.S., Tanios, B.Y., et al. (2016) Hyperuricemia, Hypertension, and Chronic Kidney Disease: An Emerging Association. Current Hypertension Reports, 18, 74. https://doi.org/10.1007/s11906-016-0684-z
|
[14]
|
Su, H., Yang, C., Liang, D., et al. (2020) Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury. BioMed Research International, 2020, Article ID: 5817348. https://doi.org/10.1155/2020/5817348
|
[15]
|
Khanna, D., Fitzgerald, J.D., Khanna, P.P., et al. (2012) 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care & Research (Hoboken), 64, 1431-1446. https://doi.org/10.1002/acr.21772
|
[16]
|
Khanna, D., Khanna, P.P., Fitzgerald, J.D., et al. (2012) 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis. Arthritis Care & Research (Hoboken), 64, 1447-1461. https://doi.org/10.1002/acr.21773
|
[17]
|
Becker, M.A., Kisicki, J., Khosravan, R., et al. (2004) Febuxostat (TMX-67), a Novel, Non-Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers. Nucleosides Nucleotides Nucleic Acids, 23, 1111-1116. https://doi.org/10.1081/NCN-200027372
|
[18]
|
Zennaro, C., Tonon, F., Zarattini, P., et al. (2017) The Renal Phenotype of Allopurinol-Treated HPRT-Deficient Mouse. PLOS ONE, 12, e173512. https://doi.org/10.1371/journal.pone.0173512
|
[19]
|
Chen, C., Lü, J. and Yao, Q. (2016) Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Medical Science Monitor, 22, 2501-2512. https://doi.org/10.12659/MSM.899852
|
[20]
|
White, W.B., Saag, K.G., Becker, M.A., et al. (2018) Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England Journal of Medicine, 378, 1200-1210. https://doi.org/10.1056/NEJMoa1710895
|
[21]
|
Jordan, A. and Gresser, U. (2018) Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat. Pharmaceuticals (Basel), 11, 51. https://doi.org/10.3390/ph11020051
|
[22]
|
倪青. 高尿酸血症和痛风病证结合诊疗指南(2021-01-20) [J]. 世界中医药, 2021, 16(2): 183-189.
|
[23]
|
Kimura, K., Hosoya, T., Uchida, S., et al. (2018) Febuxostat Therapy for Patients with Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. American Journal of Kidney Diseases, 72, 798-810.
https://doi.org/10.1053/j.ajkd.2018.06.028
|
[24]
|
Kim, A., Kim, Y., Kim, G., et al. (2020) Comparison of Persistence Rates between Allopurinol and Febuxostat as First-Line Urate-Lowering Therapy in Patients with Gout: An 8-Year Retrospective Cohort Study. Clinical Rheumatology, 39, 3769-3776. https://doi.org/10.1007/s10067-020-05161-w
|